GI Complications in Cancer Immunotherapy Patients
NCT02784366 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2022-04-05
Summary
The purpose of this study is to establish a prospective observational cohort of cancer immunotherapy patients with GI side effects in order to identify biomarkers that predict GI complications due to treatment.
Conditions
- Malignant Melanoma
Sponsors & Collaborators
- collaborator OTHER
-
Massachusetts General Hospital
lead OTHER
Principal Investigators
-
Michael Dougan, MD, PhD · Massachusetts General Hospital
-
Ryan J Sullivan, MD · Massachusetts General Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-08-31
- Primary Completion
- 2024-03-31
- Completion
- 2024-03-31
Countries
- United States
Study Locations
More Related Trials
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT01906632 ·Status: COMPLETED ·Phase: NA
-
Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer
NCT03410732 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies
NCT02880046 ·Status: UNKNOWN
-
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine
NCT00176761 ·Status: TERMINATED ·Phase: PHASE2
-
Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs
NCT03984318 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Investigating The Experiences of Patients In Immunotherapy Clinical Trials
NCT05435365 ·Status: NOT_YET_RECRUITING
-
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
NCT04550663 ·Status: UNKNOWN ·Phase: PHASE1
-
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer
NCT05539365 ·Status: WITHDRAWN ·Phase: PHASE2
-
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
NCT04266093 ·Status: ENROLLING_BY_INVITATION
-
Immunotherapy & Me
NCT03347058 ·Status: COMPLETED ·Phase: NA
-
Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy.
NCT05450367 ·Status: COMPLETED
-
Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)
NCT01671592 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
NCT00458536 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
NCT01884168 ·Status: COMPLETED
-
Immune Profiling for Cancer Immunotherapy Response
NCT06116032 ·Status: RECRUITING
-
Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies
NCT06626269 ·Status: RECRUITING ·Phase: NA
-
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
NCT01875653 ·Status: TERMINATED ·Phase: PHASE3
-
Immune Resistance Interrogation Study
NCT04243720 ·Status: RECRUITING
-
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
NCT04960059 ·Status: COMPLETED
-
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma
NCT00576641 ·Status: COMPLETED ·Phase: PHASE1
-
Early Detection of Complications During Immunotherapy for Haematological Malignancy
NCT06377059 ·Status: RECRUITING ·Phase: NA
-
Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma
NCT01348256 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunotherapy in Patients With Early dMMR Rectal Cancer
NCT05732389 ·Status: RECRUITING ·Phase: PHASE2
-
The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma
NCT00459069 ·Status: COMPLETED ·Phase: PHASE1